PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Ozenoxacin→

Ozenoxacin PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
245765-41-7
Molecular formula
C21H21N3O3
Molecular weight
363.4 g/mol
Drug class
Non-fluorinated quinolone antibacterialtopical DNA gyrase and topoisomerase IV inhibitor
Mechanism of action
Inhibits bacterial DNA gyrase and topoisomerase IV, enzymes required for DNA replication and repair, producing bactericidal activity against susceptible skin pathogens including Staphylococcus aureus and Streptococcus pyogenes.
Indications / reported uses
  • Topical treatment of impetigo due to susceptible Staphylococcus aureus or Streptococcus pyogenes in adults and paediatric patients aged 2 months and older under the US product indication

Sources: US DailyMed — XEPI (ozenoxacin) · US FDA prescribing information · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Ozenoxacin PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Ozenoxacin Permitted Daily Exposure (PDE) report (the Ozenoxacin PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Ozenoxacin Occupational Exposure Limit (OEL) report (the Ozenoxacin OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.